Melatonin and Cardiovascular Risk
Melatonin is not recommended for routine use in adults with cardiovascular disease or risk factors based on current clinical practice guidelines, though emerging evidence suggests it may be safe and potentially beneficial in specific cardiac contexts when used appropriately.
Guideline-Based Recommendations
The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline explicitly recommends against using melatonin as a treatment for sleep onset or sleep maintenance insomnia in adults 1. This is a weak recommendation based on very low quality evidence showing that harms approximately equal benefits, with trials evaluating 2 mg doses 1. The American College of Physicians (2016) similarly found insufficient evidence to determine the efficacy of melatonin for chronic insomnia 2, 1.
These guidelines do not specifically address cardiovascular safety but establish that melatonin lacks demonstrated efficacy for its most common indication, which is critical context when evaluating cardiovascular risk-benefit.
Cardiovascular Safety Evidence: The Contradictory Landscape
Emerging Safety Concerns
Recent unpublished data from a large electronic health record study (2025) reported a concerning association between long-term melatonin use (≥1 year) and increased risk of new-onset heart failure, heart failure hospitalization, and all-cause mortality in adults with insomnia 3. However, this remains conference abstract data that has not undergone peer review or independent validation 3, 4.
A 2026 case report documented ventricular arrhythmia in a 63-year-old man taking 10 mg daily melatonin, with complete symptom resolution after discontinuation 5. The systematic review accompanying this case identified similar arrhythmic events associated with melatonin supplementation 5.
Counterbalancing Evidence
A 2026 NHANES analysis found no significant association between recent melatonin use and prevalent cardiovascular disease or heart failure in a nationally representative U.S. adult cohort 4. This provides important contextual counterweight to alarm signals, though observational data cannot establish definitive safety.
A 2026 meta-analysis of 14 randomized trials (n=1027) showed melatonin significantly improved change in left ventricular ejection fraction (mean difference: 3.95 percentage points; 95% CI: 1.70-6.20), particularly in coronary artery bypass grafting settings 6. However, benefits were inconsistent across other cardiovascular endpoints including troponin and infarct size 6.
Specific Cardiovascular Considerations
Blood Pressure Effects
In patients with coronary artery disease and non-dipper blood pressure patterns, 5 mg melatonin normalized blood pressure in 35% of patients but caused both nocturnal BP decrease AND daytime BP increase 7. Critically, 12.5% developed non-optimal effects (extreme- or reverse dippers) 7. Melatonin should not be used in patients with high-normal BP values due to risk of inducing arterial hypertension 7.
Dose-Dependent Considerations
A 2019 systematic review found adverse cardiovascular events (blood pressure, heart rate changes) appear influenced by dosage, dose timing, and potential interactions with antihypertensive drugs 8. A 2024 review suggests cytoprotective cardiovascular benefits may require very high doses (100-200 mg/day range based on allometric calculations), far exceeding typical supplementation doses 9.
Proposed Mechanisms of Harm
Potential mechanisms for cardiovascular adverse effects include 5, 3:
- Melatonin receptor-mediated effects on cardiac conduction
- Disruption of sleep architecture paradoxically worsening cardiovascular stress
- Pharmacokinetic variability and genetic predisposition
- Prolactin-mediated pathway: Melatonin may increase prolactin release, which could theoretically be cleaved to cardiotoxic 16-kDa fragments in patients with oxidative stress (analogous to peripartum cardiomyopathy mechanism) 3
Clinical Algorithm for Cardiovascular Risk Assessment
Do NOT Use Melatonin If:
- High-normal blood pressure (risk of inducing hypertension) 7
- History of cardiac arrhythmias (case reports of conduction disturbances) 5
- Taking antihypertensive medications without BP monitoring capability 8
- Non-dipper BP pattern without ability to monitor 24-hour ambulatory BP 7
Use With Extreme Caution and Monitoring If:
- Established coronary artery disease requiring 24-hour BP monitoring before and during treatment 7
- Heart failure (given unpublished safety signal) 3
- Multiple cardiovascular risk factors (diabetes, metabolic syndrome) 8
If Considering Use Despite Lack of Guideline Support:
- Start with lowest effective dose (1-2 mg, not the 5-10 mg commonly used)
- Time dosing to natural circadian rhythms (2-3 hours before desired sleep time) 8
- Monitor BP if any cardiovascular history, ideally with 24-hour ambulatory monitoring 7
- Limit duration given long-term safety signal (avoid ≥1 year continuous use) 3
- Document baseline cardiovascular symptoms and ECG if high-risk 5
- Discontinue immediately if new cardiovascular symptoms develop 5
Critical Caveats
Confounding-by-indication is severe: Melatonin users often have insomnia, depression, anxiety, and higher healthcare utilization—all independent cardiovascular risk factors 4. Observational associations may reflect underlying disease severity rather than melatonin effects.
Quality of evidence is poor: The AASM guideline rated melatonin evidence as very low quality 1. Most cardiovascular data comes from small trials, case reports, or observational studies vulnerable to bias 5, 8, 4, 6.
Over-the-counter status creates monitoring gaps: Patients often self-prescribe without medical supervision, using variable doses and formulations 4. Always document OTC melatonin use in cardiovascular patients.
Bottom Line for Clinical Practice
Given that major sleep medicine guidelines recommend against melatonin for insomnia 1, emerging (though unconfirmed) heart failure safety signals 3, documented arrhythmia cases 5, and blood pressure concerns 7, the burden of proof for cardiovascular safety has not been met. In patients with cardiovascular disease or risk factors, prioritize evidence-based insomnia treatments (cognitive-behavioral therapy for insomnia as first-line 1) and FDA-approved hypnotics when pharmacotherapy is needed. If melatonin is already being used, counsel patients on the uncertain cardiovascular risk profile and consider discontinuation or close monitoring based on individual risk factors.